Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Centro De Inmunología Molecular has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 2 distinct examiners in 2 distinct art units, indicating separate examination paths.
PAK, MICHAEL D is the busiest examiner, with 1 pending action. Counsel should assess each file independently because the data shows no shared examiner or art-unit assignment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +30.2% |
| ALLEN, MICHAEL D | 1 | 31.7% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916910 | ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19 | ALLEN, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569714 | USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE | PAK, MICHAEL D | — |
| 17916910 | ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19 | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569714 | USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE | PAK, MICHAEL D | 1674 | Other | Non-Final OA | — | Pending | Dec 13, 2023 |
| 17916910 | ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19 | ALLEN, MICHAEL D | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentro De Inmunología Molecular has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Michael D Pak has the most, with 1 of Centro De Inmunología Molecular's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.